Laura Towart: Can anti-parasitic drugs aid in the fight against cancer?
Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post on LinkedIn:
“Can anti-parasitic drugs aid in the fight against cancer?
Im pleased to report that Vivan Therapeutics has validated a novel anti-cancer therapeutic combination, independently, and in partnership with the Vall d’Hebron Institute of Oncology (VHIO).
In the era of most notable technological advances in medicine, cancer, one of the oldest diseases known by humankind still has no solution, claiming over 10m lives annually.
While treatment outcomes have significantly improved for a very few types of cancers over the last decades, most tumour types are still highly deadly. One example is pancreatic cancer. In the 70s’, the 10-years survival rate for pancreatic cancer was around 1%. Today, it is still a daunting 1%. One strong reason behind the lack of effective therapies for this cancer is the occurrence of activating mutations in the oncogene KRAS, a genetic alteration present in nearly 90% of pancreatic tumours. Similarly, clinical outcomes remain extremely poor for other tumour types with highly incidence of KRAS mutations, such as colorectal and lung cancers.
For Vivan Therapeutics the mission is clear: to put an end to this historical and global malady by identifying novel cancer treatments.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023